SPONSORED CONTENT FROM EUROPE'S HEALTH DIVIDEND

Our future depends on choosing to invest in a resilient, competitive, innovative and secure environment in which society can thrive. Our human capital is the foundation of that success, the economic driver of innovation and productivity. Like any source of growth, it requires investment.

November 16, 2026 5:00 am CET

Europe’s population is aging, with an increased burden of chronic diseases: more than half of adults in the European Union are now overweight and one in six is obese.1 In parallel, we are exposed to new threats from biosecurity, the malicious use of artificial intelligence, climate-related health threats and drug-resistant superbugs.

We are not passive bystanders. European teachers, biologists, nurses and manufacturers have all played a role in developing innovations that protect our populations and help them thrive. Now is not the time to step back. We believe health research and innovation are economic drivers of Europe’s future, not discretionary costs. Backing research in health as a pillar of our future in a global race is the right choice. It enables Europe to lead and support sustainable growth, as a pillar of the new architecture of global health.

We believe health research and innovation are economic drivers of Europe’s future, not discretionary costs.

The evidence is all around us. A vaccine developed against tuberculosis has been a frontline bladder cancer treatment for over 40 years,2 technology first developed for a malaria vaccine now helps protect millions against shingles,3 and mRNA research, developed over decades, enabled Europe’s fastest-ever vaccine response to Covid-19.4 Scientific progress rarely remains confined to the place or problem where it begins.

Public budgets are under pressure, but these achievements show what investment in global health research can deliver. Pressure can be a catalyst, focusing minds, sharpening priorities and turning constraints into innovative breakthroughs. Too often, the debate is framed in terms of what Europe gives. Too rarely is it framed in terms of what Europe and its people receive in return. With commitment, we can find pragmatic ways to maximize our investments as a union.

Building on its strengths in life sciences, Europe can advance its health sovereignty and seize the emerging opportunities in scientific discovery, next-generation vaccines and biomanufacturing. Basic and applied research become new technologies, intellectual property, skilled jobs and revenues that protect European health, growth and wealth. Together, these returns are Europe’s Health Dividend.

Europe’s health, security and prosperity depend on its ability to contribute to, and benefit from, global networks of research and innovation. Retreating from global research would not reduce vulnerability; it would increase it. Investing and engaging beyond our borders is a strategic imperative for Europe.

Retreating from global research would not reduce vulnerability; it would increase it. Investing and engaging beyond our borders is a strategic imperative for Europe.

At a time when public investment must deliver its value, we can find ways to maximize the impact of European money by working and funding a shared agenda together, not as disjointed nations. Health research remains one of the clearest examples of an investment that strengthens Europe’s future while delivering benefits today.

Back Europe’s Health Dividend. Sign the declaration.

SIGNATORIES

The above column is sponsor-generated content. To learn more about our advertising solutions, click here.

Source: POLITICO Europe · Europe’s Health Dividend

At a glance

Topic
Health
Country
🇧🇪 BE
Publisher language
EN
Added to Allnira